Vir Biotechnology (NASDAQ:VIR) Trading Down 3.8% – What’s Next?

Vir Biotechnology, Inc. (NASDAQ:VIR) shares traded down 3.8% during trading on Friday . The company traded as low as $10.81 and last traded at $10.78. 201,759 shares changed hands during trading, a decline of 95% from the average session volume of 4,411,654 shares. The stock had previously closed at $11.20.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on VIR shares. Leerink Partners boosted their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Friday, January 10th. JPMorgan Chase & Co. lifted their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Barclays dropped their price objective on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.83.

Vir Biotechnology Stock Performance

The firm has a market capitalization of $1.46 billion, a PE ratio of -2.71 and a beta of 0.51. The business’s 50 day moving average is $8.46 and its two-hundred day moving average is $8.47.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The company had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Vir Biotechnology’s revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.22) earnings per share. As a group, equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Insider Activity

In other news, Director Vicki L. Sato sold 10,960 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the transaction, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. The trade was a 0.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 14,786 shares of company stock worth $170,172 over the last ninety days. Company insiders own 15.60% of the company’s stock.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of VIR. American Century Companies Inc. increased its position in shares of Vir Biotechnology by 12.7% in the second quarter. American Century Companies Inc. now owns 168,235 shares of the company’s stock worth $1,497,000 after purchasing an additional 18,967 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Vir Biotechnology by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after buying an additional 58,360 shares in the last quarter. Hsbc Holdings PLC increased its holdings in shares of Vir Biotechnology by 148.3% in the 2nd quarter. Hsbc Holdings PLC now owns 46,222 shares of the company’s stock worth $405,000 after buying an additional 27,605 shares during the last quarter. Public Sector Pension Investment Board increased its holdings in shares of Vir Biotechnology by 7.2% in the 2nd quarter. Public Sector Pension Investment Board now owns 191,608 shares of the company’s stock worth $1,705,000 after buying an additional 12,949 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in shares of Vir Biotechnology by 6,402.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,624 shares of the company’s stock valued at $1,679,000 after buying an additional 185,723 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).